Objective To determine whether reduced growth velocity (GV) in extremely low birth weight infants is preceded by elevated inflammatory cytokines. Study Design GV was determined at 36 weeks' postmenstrual age (PMA) in 768 infants 401 to 1,000 g birth weight (BW). Association between blood cytokines measured through day of life 21 and GV was explored using linear regression models that adjusted for late-onset sepsis (LOS), BW, small for gestational age (SGA), gender, race, energy intake, and center. Results Serum interleukin-6 (IL-6) was increased at days 14 and 21 in LOS infants. LOS was associated with reduced energy intake and GV for weight (weight-GV) at 36 weeks' PMA. Linear regression analysis controlling for LOS and energy intake showed significant relationships between increased IL-6 at days 14 and 21 with reduced weight-GV at 36 weeks' PMA (p < 0.0001). The relationship between day 21 IL-6 and weight-GV was not associated with LOS (p ¼ 0.12) when controlling for BW and energy intake. Both BW (p ¼ 0.02) and energy intake (p ¼ 0.003) influenced the relationship between day 14 IL-6 and weight-GV. Conclusion IL-6 elevation during the first month of life is associated with lower weight-GV at 36 weeks' PMA and may have a direct effect upon energy balance and postnatal growth.
Very low birth weight (VLBW, 1,500 g birth weight [BW]) infants with major morbidities experience reduced growth velocity (GV) relative to comparable infants without these morbidities.
1 Late-onset sepsis (LOS) comprises the largest proportion of associated morbidities in these infants. LOS increases total energy expenditure 2 and is associated with reduced GV at 36 weeks' postmenstrual age (PMA). 3 Proinflammatory cytokines including tumor necrosis factor-alpha (TNFα) and interleukin-6 (IL-6) have been associated with intrauterine and postnatal growth restriction in several different clinical settings. 4, 5 Neonates have recently been
shown to have immature anti-inflammatory responses, resulting in reduced production of the anti-inflammatory cytokine IL-10 relative to production of the proinflammatory cytokines IL-6 and TNFα. 6, 7 Whether neonates who have experienced major morbidities may be especially prone to persistent upregulation of inflammatory cytokines and thereby reduced GV is not known. Older children with chronic relapsing inflammatory conditions including inflammatory bowel disease and juvenile rheumatoid arthritis commonly experience increases in circulating cytokines and growth failure. 8, 9 Either targeted anti-TNFα therapy or supplemental nutrition aimed at increasing protein and energy intake can return them to premorbid growth velocities. [10] [11] [12] LOS is associated with a substantial increase in circulating cytokines including IL-6, 13 and increased circulating has been associated with reduced GV in preterm infants without major morbidities. 4 We hypothesized that reduced GV in extremely low birth weight (ELBW) infants with major morbidities including LOS might therefore also be preceded by elevated inflammatory cytokines. We examined the relationship between early elevation in proinflammatory cytokines and postnatal growth outcomes in a large cohort of ELBW infants enrolled in the Neonatal Research Network (NRN) Cytokine Study.
Patients and Methods

Patient Cohort and Study Design
Data were collected prospectively for ELBW neonates (weighing 401-1,000 g at birth) who were born between 1999 and 2001 and were cared for at one of the 17 Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) NRN sites. The network maintains a registry of infants with BWs of 401 to 1,500 g who are admitted at participating centers within 14 days after birth. Trained research personnel collected maternal sociodemographic, pregnancy, and delivery data soon after birth and infant data from birth until 120 postnatal days, discharge, or death, using standardized registry forms. The institutional review board at each center approved participation in the registry, and written informed consent was obtained from the parents. This was a secondary study using the patient data and analytical results from the NICHD NRN Cytokine Study. We studied 768 of 1,067 infants in the NRN Cytokine Study who had GV data available at 36 weeks' PMA. Inclusion criterion was BW 1,000 g (ELBW) and exclusion criterion was death < 7 days of age. Eleven infants with syndromes/major malformations (including femoral hypoplasia, ambiguous genitalia, atrial septal defect, sick euthyroid syndrome, hypoplastic pulmonary arteries, hydroureter, absent septum pellucidum, hepatic hemangioendotheliomatosis involving the entire liver, congenital schizencephaly, duodenal atresia, and skeletal dysplasia) were included in the analysis. Patient data included measurements of BW, length and head circumference (HC), nutritional intake, and the occurrence of major morbidities (bronchopulmonary dysplasia [BPD] , necrotizing enterocolitis [NEC] , severe intraventricular hemorrhage [IVH] , and LOS). Total energy intake was calculated as the appropriately-weighted sum of the energy contained in administered parenteral components: dextrose, amino acids, and lipids; plus the caloric total for the consumed volume of enteral intake, expressed in kcal/kg/day. The outcomes are network-standard definitions: LOS was defined as culture positive septicemia/bacteremia diagnosed beyond 72 hours of age. Infants were considered to have NEC if they met or exceeded the modified Bell's staging criteria IIA.
IVH was based on the cranial sonogram within 28 days showing the most severe hemorrhage. Severe IVH (grade 3-4) was defined as blood/echodensity in the parenchyma (grade 4), or blood/echodensity in the ventricle with ventricular size enlarged (grade 3).
BPD was defined as supplemental oxygen at 36 weeks' PMA (including discharge or transfer on oxygen if prior to 36 weeks').
Whole blood spots on filter paper ($0.2 mL per day) were collected on days 0 (day of birth), 3 AE 1, 7 AE 1, 14 AE 3, and 21 AE 3 and frozen to À70°C. The stored blood spots were analyzed in a batch for 25 cytokines including IL-6, IL-1β, TNFα, and IL-10 using a multiplex Luminex assay (Luminex Corp., Austin, TX).
14 The working range, defined as the range of concentrations for which the coefficient of variation (CV) is < 20%, for each of these was 7.8 to 4,000 pg/mL. The intraand inter-assay CV for each cytokine were: 6.7% and 11%; 5.3% and 16%; 5.4% and 13%, and TNFα, 5.5% and 16%, respectively. Cytokine levels below or above the detection limit were assigned the value of the detection limit. For example, " < 3" was assigned a value of 3, and " > 6,400" was assigned a value of 6,400.
Analysis
All statistical analyses were performed at the NRN Data Coordinating Center (RTI International). As previously described by Patel et al
15
, growth velocity for weight was calculated in daily increments based on daily weights using the following formula: ([wgt {n + 1} -wgt {n}]
Ã 1000) / ([wgt {n} + wgt {n + 1}] / 2). When daily weights were missing, the values were divided by the number of days between the two growth measurements. The starting point for calculating GV was the day when birth weight was regained (or day 1 for infants who never lost birth weight). The overall GV for each infant was calculated by averaging all the daily GV values for that infant. The cohort was then separated by quartiles according to their growth velocity for weight (g/kg/day) through 36 weeks PMA or discharge. Since we did not have daily measurements of length and head circumference, GV-length and GV-HC were calculated as the differenced between final and initial measurements divided by the number of weeks between measurements, and were expressed in cm/wk. Within each time point, median TNFα, IL-6, IL-1, and IL-10 levels across the four GV quartiles were then compared using the nonparametric median test. Given concerns about the need to consider the influence of NEC or LOS on cytokine levels, we also compared cytokine levels at each of the time points and GV for infants who experienced LOS between days 4 to 20, after day 20, or not at all. Nonparametric median tests were used for all unadjusted comparisons of cytokine levels because of the skewed nature of these data. Adjusted analyses/regression modeling was then performed for those cytokines that showed associations with LOS group or GV quartile in the unadjusted/bivariate analyses. Linear regression modeling was performed for the effect of IL-6 or IL-10 levels at each time point on GV, while adjusting for timing of LOS/NEC (days 4-13, 14-21, 21 þ , or no LOS/NEC), BW, SGA, gender, race, center, and energy intake. The linear regression models were set up to predict overall GV (starting at date regaining BW through 36 weeks' PMA). All data were analyzed using SAS 9.1 (SAS Institute, Cary, NC), at RTI International (Research Triangle Park, NC).
Results
Clinical and Demographic Characteristics
Patient characteristics by GV quartile for weight are given in ►Table 1. Both BW and gestational age were lower in the groups with lower GV. The groups did not vary based upon frequency of SGA, male gender, African American race, or NEC. However, the frequency of BPD, grade III-IV IVH, and LOS were higher in the groups with lower GV. Length of stay was also longer in the group with the lower GV.
Energy Intake
Differences in energy intake could contribute to differences in GV, particularly if elevated cytokines increased protein and energy requirements. Energy intake was therefore examined between days 1 and 60 as a function of GV quartile for weight. As shown in ►Supplementary Table 1 (available in the online version of this article), median (interquartile [IQ] range) energy intake was reduced in GV quartile I compared with the other groups (p < 0.0001 by median test). Energy intake was also examined between days 1 and 60 as a function of timing of LOS. As shown in ►Table 2, median (IQ range) energy intake was also significantly lower for the groups with LOS compared with those without LOS both between day of life (DOL) 4 to 20 and those with LOS after DOL 20 (p < 0.0001 by median test).
Blood Cytokine Levels Stratified by Growth Velocity Quartiles
We then examined serum cytokine levels at each of the time points as a function of GV quartile. There were no significant relationships between any of the four cytokines (IL-6, IL-10, IL-1β, and TNFα) with GV quartile (see ►Supplementary 
Adjusted Analysis using Linear Regression Models
To further explore the relationship between those cytokines significantly associated with LOS in unadjusted analysis (day 14 or 21 blood IL-6, day 14 blood IL-10; see Supplementary ►Table 3, available in the online version of this article), timing of LOS, and GV, linear regression models that included BW, SGA, gender, race, center, total energy intake (day 1-60), IL-6 or IL-10 levels, and age at occurrence of LOS/NEC as covariates were examined. Blood IL-10 at day 14 was not associated (p ¼ 0.11) with weight-GV after adjustment and was not investigated further. The results from linear regressions for GV are shown in ►Table 3 for day 21 IL-6 and in ►Supplementary pg/mL increase in the level of serum IL-6. The LOS/NEC variable compared timing of infection (4-13 days, 14-20 days, 21 þ 3 days) to infants without infection. The overall p-value is also given (this is the only categorical variable with more than two levels). Significant (p < 0.0001) relationships between day 14 or 21 serum IL-6 levels and weight-GV at 36 weeks' PMA were identified. Thus, an increase of 100 pg/mL in the level of day 21 blood IL-6 was associated with a lower weight gain of $0.5 g/kg/day in weight-GV, and a similar increase in the level of day 14 blood IL-6 was associated with a lower weight gain of $0.7 g/kg/day in weight-GV. Energy intake (p ¼ 0.003) and BW (p ¼ 0.02) significantly influenced the relationship between day 14 IL-6 and weight-GV. LOS/NEC (p ¼ 0.12), energy intake between day 1 to 60, and other clinical and demographic factors considered did not influence the relationship between day 21 IL-6 and weight-GV. There was no association between day 14 IL-6 and length-GV or HC-GV. The association between day 21 blood IL-6 and length-GV approached significance (p ¼ 0.06) though the size of the effect was relatively small. Length-GV was significantly associated with energy intake. There was no association between day 21 blood IL-6 and HC-GV. However, HC-GV was significantly associated with energy intake, LOS/NEC occurring after 21 days of age, BW, SGA, and race.
Significant center variations were present in both length-GV and HC-GV.
Discussion
The period between regaining BW and hospital discharge is a critical window for preterm infants to establish an optimal GV.
16 VLBW infants with major morbidity (defined as LOS, BPD, NEC, or severe IVH) experience reduced GV relative to comparable infants without these morbidities. 1 This is reflected in a longer time to regain BW and persistently lower weight over time. For each 100 g BW interval examined between 501 to 1,500 g, LOS comprised the largest proportion of associated morbidities. 1 Therefore, LOS may be a particularly important factor associated with subsequent reduced GV in VLBW infants. Despite nutritional intake which should be sufficient to meet estimated protein and energy requirements, these infants do not exhibit catch-up growth prior to hospital discharge. 1 This suggests that factors such as circulating cytokines associated with morbidities including LOS may cause a resistance to what would otherwise be adequate nutrition.
In the current study, we found that ELBW infants who experience LOS have elevated IL-6 levels during the first month of life and reduced GV through 36 weeks' PMA when compared with ELBW infants without LOS and elevated levels of IL-6. It should be noted that the magnitude of the IL-6 effect upon weight gain was relatively modest over the range of cytokine levels measured (approximately a 0.5 g/kg/day decrease in weight gain for every 100 pg/mL increase in day 21 IL-6). Nevertheless, our results suggest that elevation in IL-6 may in fact cause a resistance to what would otherwise be adequate nutrition. Our study is in agreement with the report by Ahmad et al in which the relationship between serum IL-6, insulin-like growth factor 1 (IGF-I), and GV was explored in a prospective cohort of 51 preterm infants without comorbidities. In contrast to the current study, this group was enrolled following initial neonatal intensive care unit stabilization, after removal of all indwelling catheters, once they were receiving enteral nutrition of at least 100 kcal/kg/day. 4 During the observation period, weight and IGF-I increased while IL-6 decreased. Importantly, IGF-I and IL-6 were inversely correlated suggesting an influence of circulating IL-6 upon anabolic metabolism even in a cohort of otherwise healthy preterm infants. Regression analysis confirmed an inverse association between serum IL-6 levels and growth parameters. Inflammatory cytokines which are upregulated during an acute phase reaction, including TNFα and IL-6, have been associated with intrauterine and postnatal growth restriction in several different clinical settings. IL-6 was higher in neonates with sepsis and NEC than in neonates without infection. 17 In some studies, neonates have been shown to have immature anti-inflammatory responses characterized by reduced production of the anti-inflammatory cytokines IL-10 and transforming growth factor beta (TGF-β) relative to the proinflammatory cytokines TNFα and IL-6. 6,7 Median IL-10 was elevated at day 14 for infants with LOS but neither IL-10 nor LOS/NEC was significantly associated with GV in adjusted linear regression. Therefore, our data do not support a defect in anti-inflammatory IL-10 production contributing to persistent IL-6 elevation in preterm infants with poor growth. Even a brief infection can induce a significant nutritional deficit. Inflammation may induce a catabolic state characterized by increased metabolic rate.
18 If these extra nutritional requirements, in particular increased protein relative to energy, are not met following the infection, catch-up growth will not occur. Protein catabolism may increase during neonatal sepsis and may explain growth failure. 19, 20 Protein intake must increase from 6% of calories to 15% in order for IGF-I to increase and catch-up growth to occur following shigellosis in undernourished children. 21 This could translate into a requirement for an additional 1 g/kg/day of protein for catch-up growth to occur in VLBW infants following infection. Moreover, if a chronic inflammatory process persists, refeeding therapy will not succeed. In a study examining refeeding of malnourished elderly patients, failure of refeeding was associated with elevated circulating IL-6 and a persistent catabolic state. 22 Increased circulating levels of proinflammatory cytokines may persist for several years following a neonatal infection. For example, children who have had respiratory syncytial virus infection as infants exhibit increased circulating interferon gamma (IFNγ) levels at 6 to 10 years of age. 23 Unless chronic inflammation is identified and addressed, GV which declines during an acute infection may remain suboptimal. In this regard, the energy intake of the infants in GV quartile I or with LOS may not have been sufficient to overcome the additional demands induced by the increase in circulating IL-6. Similar to fetal HC and length sparing observed in asymmetric intrauterine growth restriction, our results suggest that postnatal energy intake may support HC and length growth before weight gain. The strengths of our study include the large prospective cohort design and the rigorous clinical data collection methods. However, we were not able to control for all factors which may affect both the incidence and severity of major morbidities and associated growth in the analysis. We did not analyze data on fortified human milk versus preterm formula. Feeding with greater than 50% of enteral calories as fortified human milk has been shown to reduce the incidence of LOS and NEC, presumably because of the presence of beneficial immune factors including immunoglobulin A and TGF-β. 24 However, this was also associated with reduced fat absorption and GV relative to preterm formula. 25 Moreover, the exploratory nature of the unadjusted/bivariate analysis, which did not control for multiple comparisons, may have overestimated differences observed. Most importantly, we did not measure circulating IL-6 beyond day 21, and so were not able to determine whether this remained chronically elevated in infants with reduced weight gain. Severity of pulmonary disease and the use of steroids for management of BPD 26 have also been shown to influence growth velocity, but our models did not include details on severity of lung disease. Dexamethasone treatment causes growth hormone GH resistance and has been shown to reduce circulating IGF-I and GV in preterm infants.
27
LOS is associated with a substantial increase in circulating cytokines including IL-6. However, IL-6 levels typically decrease precipitously in most infants with LOS within 24 hours.
13 Additional host factors may influence persistent elevation of serum IL-6 following the initial inciting event.
Genetic variation (À174 G/C) in the IL-6 gene promoter regulates IL-6 production and has been associated with variation in growth in children with Crohn's disease. 28 The IL-6 gene promoter À174 G/C genotype has also recently been associated with chorioamnionitis and sepsis in preterm infants. 24 It will be important in future-work to consider the IL-6 promoter genotype in interpreting differences in circulating IL-6 and growth in preterm infants. Our data suggest that early elevation in blood IL-6 is associated with reduced weight-GV at 36 weeks' PMA in ELBW infants. Persistent elevations of IL-6 could directly affect energy balance and postnatal growth. Assessment of this will be required to provide adequate protein and energy and potentially targeted anti-inflammatory therapy to preterm infants with reduced GV associated with chronic inflammation. 
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